Navigation Links
Einstein hosts its first stem cell institute symposium
Date:9/21/2012

September 21, 2012 (BRONX, NY) The promise of stem cells seems limitless. If they can be coaxed into rebuilding organs, repairing damaged spinal cords and restoring ravaged immune systems, these malleable cells would revolutionize medical treatment. But stem cell research is still in its infancy, as scientists seek to better understand the role of these cells in normal human development and disease.

On Friday, September 14, the Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research at Albert Einstein College of Medicine of Yeshiva University offered the Einstein community and invited guests an opportunity to hear from leading stem cell scientists investigating the dynamic field. The 2012 Einstein Stem Cell Institute Symposium featured speakers from around the globe presenting the latest research on induced pluripotent stem cells (iPS cells), cell reprogramming, as well as cancer and hematopoietic (blood-forming) stem cells.

"This symposium was an important milestone for stem cell research at Einstein and confirms our intent to contribute to advances in stem cell biology," said the event's host and organizer, Paul Frenette, M.D., director and chair of Einstein's Stem Cell Institute and professor of medicine and of cell biology.

"There has been a lot of hype in the past few years about the promise of stem cell research and some concerns that perhaps it was oversold to the public," said Dr. Frenette. "The symposium's speakers nicely illustrated the tremendous progress that has been made thus far and showed how outstanding research is helping us to realize the full potential of stem cells."

The afternoon event included four presentations:

  • George Q. Daley, M.D., Ph.D., discussed "Lin28 in Stem Cells and Disease." Dr. Daley is the Samuel E. Lux IV Professor of Hematology/Oncology and director of the Stem Cell Transplantation Program at Boston Children's Hospital; professor of biological chemistry and molecular pharmacology, of medicine, and of pediatrics at Harvard Medical School; and an investigator of the Howard Hughes Medical Institute.

  • Kathrin Plath, Ph.D., gave a talk on the "Mechanisms of Reprogramming of Pluripotency." Dr. Plath is associate professor of biological chemistry at the University of California, Los Angeles's David Geffen School of Medicine.

  • Toshio Suda, M.D., Ph.D., professor of cell differentiation at the Graduate School of Medicine, Keio University in Tokyo, Japan, presented "Hematopoietic Stem Cells in Hypoxic Niches."

  • Andreas Trumpp, Ph.D., professor and head of the division of stem cells and cancer, and managing director of the Heidelberg Institute for Stem Cell Technology and Experimental Medicine in Heidleberg, Germany, discussed "Circulating Metastasis-initiating Cells in Breast Cancer."

Dr. Frenette closed the event by thanking the speakers and the 100 attendees in the Ethel and Samuel J. LeFrak Auditorium, as well as additional attendees viewing the proceedings from overflow rooms in Einstein's Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion.

"We hope this symposium will foster collaborations between Einstein faculty members and leaders in the field, and embolden our developing program toward new heights of research excellence," said Dr. Frenette.

Dr. Frenette will continue the stem cell discussion at the New York Stem Cell Foundation's (NYSTEM) seventh annual Translational Stem Cell Research Conference, on October 10 and 11. Dr. Frenette is chair of the "Cancer and Blood Disease" session, which features Elaine Fuchs, Ph.D., of Rockefeller University; Ravi Majeti, M.D., Ph.D., of Stanford University; and Joanne Kurtzberg, M.D., of Duke University.

Dr. Frenette was also recently elected vice-president of the International Society of Experimental Hematology (ISEH) and will become president of ISEH in 2015.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Einstein researcher receives $10.8 million grant to study toxic blood reactions caused by hemoglobin
2. Danforth Plant Science Center hosts 14th Annual Fall Symposium
3. FAPESP hosts meeting to discuss IPCC SREX report in São Paulo, Brazil
4. Urinary tract infections steal from hosts defense arsenals
5. Parasitic plants steal genes from their hosts
6. MADRID-MIT M+Vision Consortium hosts Biomedical Innovation Conference 2012
7. Ohio state hosts national energy conference
8. Fracking and Health Impact Assessments -- IOM hosts workshop April 30 and May 1
9. Survival of the fittest -- ESF hosts session on the challenges of life in extreme environments
10. Professor publishes on first-ever imaging of cells growing on spherical surfaces
11. Columbia awarded 1 of first Provocative Questions grants from NCI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology: